Gujarat Kidney And Super Speciality Limited has delivered a robust financial performance for the quarter ended 31 December 2025, demonstrating strong operational efficiency across its healthcare services portfolio. The company, which operates in the pharmaceutical trading segment, reported encouraging results on both standalone and consolidated bases.

Standalone Financial Performance

The company's standalone operations showed solid growth momentum during the quarter. Key financial metrics highlight the operational strength of the core business.

For the nine-month period ended 31 December 2025, the standalone business generated revenue from operations of ₹3,085.70 lacs compared to ₹2,715.08 lacs in the corresponding period of the previous year, representing growth of 13.65%. Net profit for the nine-month period stood at ₹853.36 lacs versus ₹784.42 lacs in the previous year.

Consolidated Financial Results

The consolidated performance, which includes subsidiaries and entities under control, demonstrated even stronger growth trajectory. The consolidated entity encompasses Gujarat Surgical Hospital, Surya Hospital and ICU, Raj Palmland Hospital Private Limited, and Harmony Medicare Private Limited.

Operational Efficiency and Cost Management

The company maintained effective cost control across key expense categories. On a standalone basis, total expenses for the quarter were ₹662.89 lacs compared to ₹653.33 lacs in the previous quarter. Employee benefits expense stood at ₹143.45 lacs, while depreciation and amortization expense was ₹74.73 lacs.

On the consolidated front, the company managed total expenses of ₹1,827.99 lacs during the quarter, with employee benefits expense at ₹398.45 lacs and other expenses at ₹931.37 lacs. The finance costs were well-controlled at ₹59.85 lacs for the consolidated entity.

Auditor Review and Regulatory Compliance

The financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 14 February 2026. The results have been subjected to limited review by statutory auditors Y M Shah & Co., who issued an unmodified limited review report for both standalone and consolidated financial results.

The company continues to maintain compliance with all regulatory requirements under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The financial statements have been prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013.

Gujarat Kidney and Super Speciality has announced major strategic acquisitions that will expand its healthcare operations. The company's board has approved two significant purchases that demonstrate its growth strategy in the healthcare sector.

Strategic Acquisitions Overview

The board has greenlit the acquisition of majority stakes in two healthcare entities, representing a substantial investment in expanding the company's operational capabilities.

Investment Breakdown

The larger of the two acquisitions involves Patel Hospital, where Gujarat Kidney and Super Speciality will acquire a 51% controlling stake for ₹88 million. This represents the majority of the total investment and indicates the strategic importance of hospital operations to the company's expansion plans.

The second acquisition focuses on Patel Pharmacy, where the company will secure a 51% stake for ₹37 million. This pharmacy acquisition complements the hospital purchase, creating a more integrated healthcare service offering.

Strategic Implications

These acquisitions position Gujarat Kidney and Super Speciality to control majority stakes in both entities, providing significant influence over operational decisions and strategic direction. The combined ₹125 million investment represents a substantial commitment to expanding the company's healthcare ecosystem through strategic partnerships and acquisitions.